GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (STU:7RG0) » Definitions » Stock Based Compensation

Regulus Therapeutics (STU:7RG0) Stock Based Compensation : €4.51 Mil (TTM As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regulus Therapeutics Stock Based Compensation?

Regulus Therapeutics's Stock Based Compensation for the three months ended in Jun. 2024 was €1.74 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 was €4.51 Mil.


Regulus Therapeutics Stock Based Compensation Historical Data

The historical data trend for Regulus Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Stock Based Compensation Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.06 2.15 2.58 2.06 2.57

Regulus Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.91 0.95 0.91 1.74

Regulus Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.51 Mil.


Regulus Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Regulus Therapeutics Business Description

Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Regulus Therapeutics Headlines

No Headlines